Option chain shows key data for OS Therapies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for OS Therapies.

OS Therapies (AMEX:OSTX) Stock, Option Chain

OS Therapies

OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the significant need for new treatments in cancers of the bone in children and young adults.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABLV

ALTS

AMIX

APDN

BFRI

CING

DGLY

FOXA

FUBO

GOVX

MREO

NVOS

OSTX

QNCX

SPRC

VRAX

VSME

XPER

ZCAR

Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

wall street ai9

Earnings

Eurozone

Commodities

AAPL

BIAF

GPAK

VINE

VSEE

XCUR

Dow Dips Over 400 Points; Apple Posts Upbeat Earnings

xr:d:DAFqe777JJc:2,j:3049335502123804312,t:23080311

AKAN

AMZN

DASH

INTC

LXRX

MELI

MUFG

OPEN

PCOR

PITA

SNAP

TEAM

TNDM

VCNX

Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket

OS Therapies Inc

CRH today announced the acquisition of Dutra Materials in San Rafael, California. This acquisition expands CRH's Americas Materials Solutions business and enhances its ability to provide integrated solutions to customers in northern California.
Dutra Materials complements CRH's Americas Materials Solutions business in the Western U.S., bringing additional strategic aggregate reserves and asphalt production capabilities to service the northern California construction market.

CRH Continues Expansion In California With Dutra Materials Acquisition; No Financial Terms Disclosed

In August 2024 we (&quot;Kaspi.kz&quot;) submitted a non-binding letter of interest to Uzbekistan&#39;s State Assets Management Agency (&quot;SAMA&quot;), indicating our interest in participating in the privatisation of the National Interbank Processing Center (&quot;Humo&quot;). At this time, we are not proceeding further in the process.
Uzbekistan&#39;s economy is growing fast and its government is pursuing an attractive reform agenda. Kaspi.kz&#39;s innovative digital products improve the everyday lives of consumers and merchants and we will continue to look for opportunities to play a part in Uzbekistan&#39;s exciting digital transformation.

Global

KSPI

In August 2024 Kaspi.kz Submitted A Non-Binding LOI To Uzbekistan's State Assets Management Agency, Indicating Our Interest In Participating In The Privatization Of The National Interbank Processing Center; At This Time, The Co Is Not Proceeding Further In The Process

Buybacks

Bunge Expands Share Repurchase Program By $500M, Increasing Total Authorization To $1.3B Following Sale Of Sugar And Bioenergy JV Interest; CEO Highlights Commitment To Capital Allocation

Macquarie analyst Paul Golding maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Outperform and raises the price target from $130 to $146.

Price Target

Analyst Ratings

Macquarie Maintains Outperform on Live Nation Entertainment, Raises Price Target to $146

AppTech Payments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APCX#NASDAQ">APCX</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 46.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $43.00 thousand in sales this quarter. This is a 69.29 percent decrease over sales of $140.00 thousand the same period last year.

Earnings Misses

APCX

AppTech Payments Q3 EPS $(0.08) Misses $(0.06) Estimate, Sales $43.00K Down From $140.00K YoY

Cathie Wood, CEO of asset management giant Ark Invest, suggested that Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price could hit a base target of $650,000 by 2030, with an optimistic scenario reaching <a href="https://www.benzinga.com/money/bitcoin-price-prediction">as high as $1.5 million</a>. 
What Happened: Wood, a long-time Bitcoin proponent who first invested in the digital asset in 2015, attributes the surge in Bitcoin&#8217;s price to two primary factors: regulatory relief on the horizon and Bitcoin's growing distinction from other assets.
In an <a href="https://www.youtube.com/watch?v=RW2cb5KGaTg">interview</a> with CNBC on Friday, Wood said she sees institutional interest in Bitcoin intensifying, with asset allocators increasingly recognizing its unique behavior compared to traditional assets.
Ark Invest, which was the first public asset manager to gain Bitcoin exposure at $250 in 2015, maintains an optimistic outlook for the cryptocurrency's future.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41799045/ark-invests-cathie-wood-joins-call-for-strategic-bitcoin-reserve-gives-thumbs-up-to-cynthi">Ark Invest&#8217;s Cathie Wood Joins Call For Strategic Bitcoin Reserve, Gives Thumbs Up To Cynthia Lummis&#8217; Plan</a>
Wood's prediction ties into Ark Invest's broader outlook, which also includes optimism about the potential for the <a href="https://www.benzinga.com/24/11/41928272/cathie-woods-ark-invest-foresees-crypto-industry-boost-under-incoming-trump-administration">upcoming Donald Trump administration</a> to provide clearer regulations for the cryptocurrency industry in the United States.
With the end of current SEC Chair Gary Gensler&#8216;s term, the firm <a href="https://www.youtube.com/watch?v=RW2cb5KGaTg">anticipates</a> a more crypto-friendly SEC and a shift away from "regulation by enforcement," which could provide the regulatory clarity needed to spur further institutional investment.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/41891628/ross-gerber-cathie-wood-or-gary-black-whose-funds-stack-up-against-sp-500s-gains-in-2024">Ross Gerber, Cathie Wood Or Gary Black? Whose Funds Stack Up Against S&amp;P 500&#8217;s Gains In 2024?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin To Hit Up To $1.5 Million By 2030, Says Cathie Wood

<a href="https://pr.report/4a65">Gladstone Commercial Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOD#NASDAQ">GOOD</a>) (the &quot;Company&quot;) announced that Terry Lee Brubaker will be retiring as Chief Operating Officer of the Company effective December 2, 2024. Mr. Brubaker is also retiring as director and executive officer of Gladstone Management Corporation, the Company&#39;s investment adviser, and as a member of the board of managers and an executive officer of Gladstone Administration, LLC, the Company&#39;s administrator, also effective December 2, 2024. Following Mr. Brubaker&#39;s departure, Michael LiCalsi, the Company&#39;s General Counsel and Secretary, who also serves as Gladstone Administration&#39;s President, General Counsel and Secretary, will assume certain additional operational responsibilities while Gladstone Management will conduct a national search for a Chief Investment Officer to fill Mr. Brubaker&#39;s investment committee responsibilities.

Management

GLAD

GOOD

Gladstone Announces Retirement Of COO Terry Lee Brubaker, Effective December 2, 2024; Michael LiCalsi, The Co's General Counsel And Secretary, Who Also Serves As Gladstone Administration's President, General Counsel And Secretary, Will Assume Certain Additional Operational Responsibilities

Insider Trades

Constellation Brands Director Richard Sands Sells 59,637 Shares At Average Price Of $240.38, Totaling $14.34M

LAND

Gladstone Land Announces Retirement Of COO Terry Lee Brubaker

<a href="https://www.globenewswire.com/Tracker?data=BVJO5xwsj0LDrAwUh3f-vBWd8O-_SqCpBG0OQjNTLTl8NV_twYqnXWKH3Tw11TbMrVsZnk_gKCIf66hPIR6PeWqOselKtKA0MlifgOq2mRRbk4p4SQOnMcFhljd8IDlL">Perspective Therapeutics, Inc.</a>&nbsp;("Perspective" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium taking place November 21-23, 2024 in Chicago.
The presentation entitled "Preliminary safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs)" will be presented by Richard L. Wahl, MD, (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) on Friday, November 22, 2024 at 9:05 am CT.&nbsp;&nbsp; Results of the study are also available as a poster (number C-37) at the NANETS symposium.

Biotech

General

CATX

Perspective Therapeutics To Discuss Data On [212Pb]VMT-α-NET Presented At The 2024 NANETS Multidisciplinary NET Medical Symposium On November 21, 2024

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4304665-1&amp;h=2441800747&amp;u=http%3A%2F%2Fwww.federalrealty.com%2F&amp;a=Federal+Realty+Investment+Trust">Federal Realty Investment Trust</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) announced today that Jeffrey S. Berkes, the Company's President and Chief Operating Officer, will be leaving the company effective December 31, 2024. Don Wood, Federal's Chief Executive Officer, commented, "Jeff has been my trusted partner and good friend here at Federal for the past 24 years and has been instrumental in growing the company and positioning the company as a leader in the industry. He's one of the finest professionals and human beings in our business. I'll surely miss working with him on a daily basis." Mr. Wood will reassume the additional position of President of the Company. The position of Chief Operating Officer will not be backfilled.
Wendy Seher, the Eastern Region President and Chief Operating Officer, a 22-year company veteran, and Jeff Kreshek, the Western Region President and Chief Operating Officer, a 13-year company veteran will continue in their senior operating roles at the Company and report directly to Mr. Wood.

Federal Realty Announces Jeffrey S. Berkes, The Company's President And Chief Operating Officer, Will Be Leaving The Company Effective December 31, 2024; Don Wood Will Reassume The Additional Position Of President Of The Company. The Position Of Chief Operating Officer Will Not Be Backfilled.

ADVM

Adverum Biotechnologies Schedules Webcast For November 18 To Present 52-Week LUNA Phase 2 And 4-Year OPTIC Clinical Data, Along With Key Pivotal Program Design

Flux Power Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>), a developer of advanced lithium-ion energy storage solutions for electrification of commercial and industrial equipment, today provided an update regarding its previously discussed restatement process and subsequent SEC filings for the fiscal fourth quarter and year ended June 30, 2024, and the fiscal first quarter ended September 30, 2024.
On September 5, 2024, Flux announced that it had identified approximately $1.7 million of excess and obsolete inventory primarily related to product innovation and design of its products during a period of rapid growth over the last several years. A further detailed review of this and related items has resulted in estimated noncash inventory write-downs of approximately $4.4 million and related noncash warranty related items of approximately $0.5 million, totaling adjustments of approximately $4.9 million. This impact is not a one-time adjustment but impacting multiple quarters over multiple years. To properly reflect the obsolete inventory, the Company is currently in the process of restating previously issued financial statements for fiscal year 2023 and the interim periods of fiscal year 2024, which will be reflected in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2024. The Flux team has completed its internal review of the restatements and 10-K and is working with its auditors to file them as soon as practicable, which reflects a large body of work over an extended period of time. Upon completion, Flux will work to complete the 10-Q filing for the quarter ending September 30, 2024.

FLUX

Flux Identifies $4.9M In Noncash Adjustments For Obsolete Inventory And Warranty Items, Plans To Restate FY23 And FY24 Financials; 10-K And 10-Q Filings Pending Auditor Review

Lakeside Holding Limited Q1 Total Revenues $4,148,476, Down 1.6% YoY, EPS $(0.18) vs $(0.05) YoY

<h3>Gainers</h3>
<ul>
<li>Legacy Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LGCY#AMEX">LGCY</a>) shares moved upwards by 23.0% to $6.89 during Friday's pre-market session. The market value of their outstanding shares is at $78.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) shares rose 19.37% to $0.96. The market value of their outstanding shares is at $9.4 million. </li>
<li>Despegar.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) stock rose 10.96% to $16.49. The company's market cap stands at $1.1 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) shares rose 7.62% to $0.43. The market value of their outstanding shares is at $27.7 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) stock increased by 7.09% to $0.9. The company's market cap stands at $103.9 million. </li>
<li>WeRide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRD#NASDAQ">WRD</a>) shares increased by 6.98% to $16.89. The company's market cap stands at $4.6 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Digital Brands Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) stock decreased by 22.8% to $0.1 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>SRIVARU Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares decreased by 17.15% to $0.02. The market value of their outstanding shares is at $10.2 million. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) stock declined by 12.0% to $1.1. The company's market cap stands at $22.2 million. </li>
<li>Destination XL Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXLG#NASDAQ">DXLG</a>) stock decreased by 8.67% to $2.74. The market value of their outstanding shares is at $159.6 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) shares decreased by 8.66% to $3.8. The company's market cap stands at $157.0 million. </li>
<li>Boqii Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock declined by 8.55% to $0.44. The company's market cap stands at $2.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

DBGI

DESP

DXLG

LGCY

MAMO

NRDY

SVMH

TCTM

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock increased by 71.0% to $0.32 during Friday's pre-market session. The company's market cap stands at $48.1 million. </li>
<li>QT Imaging Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTI#NASDAQ">QTI</a>) shares moved upwards by 18.58% to $0.58. The company's market cap stands at $12.4 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares rose 18.02% to $0.77. </li>
<li>Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) stock rose 14.17% to $7.49. The market value of their outstanding shares is at $399.2 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares rose 14.04% to $1.99. The market value of their outstanding shares is at $50.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock increased by 14.02% to $4.96. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares fell 71.9% to $0.45 during Friday's pre-market session. The market value of their outstanding shares is at $1.5 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares decreased by 60.02% to $0.14. The market value of their outstanding shares is at $11.6 million. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock declined by 31.31% to $2.15. The market value of their outstanding shares is at $106.4 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) shares declined by 20.85% to $0.76. The market value of their outstanding shares is at $2.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 17.66% to $0.3. The company's market cap stands at $1.8 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares decreased by 13.44% to $0.24. The company's market cap stands at $5.1 million. As per the news, the Q3 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

CERO

CTCX

EYEN

GANX

ALPS ETF Trusthen & Steers Global Realty Majors ETF

ISPC

TCBP

TFFP

TIVC

TKNO

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Simpple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>) stock moved upwards by 42.7% to $1.26 during Friday's pre-market session. The company's market cap stands at $20.4 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock increased by 25.62% to $0.44. The market value of their outstanding shares is at $40.7 million. </li>
<li>1847 Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#AMEX">EFSH</a>) shares rose 19.22% to $0.57. </li>
<li>FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) shares moved upwards by 18.4% to $8.3. The market value of their outstanding shares is at $169.1 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) shares rose 12.04% to $2.14. The market value of their outstanding shares is at $14.6 million. The company's, Q3 earnings came out yesterday. </li>
<li>HUHUTECH International Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUHU#NASDAQ">HUHU</a>) shares rose 6.66% to $4.8. The market value of their outstanding shares is at $101.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) stock declined by 25.0% to $0.9 during Friday's pre-market session. The company's market cap stands at $28.2 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares decreased by 19.72% to $2.77. The company's market cap stands at $1.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) stock fell 14.81% to $0.66. The company's market cap stands at $210.0 million. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>Fusion Fuel Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTOO#NASDAQ">HTOO</a>) stock fell 14.7% to $0.43. The company's market cap stands at $8.4 million. </li>
<li>AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares fell 13.41% to $3.1. The market value of their outstanding shares is at $2.6 million. </li>
<li>Primech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMEC#NASDAQ">PMEC</a>) shares declined by 12.63% to $0.69. The company's market cap stands at $26.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQMS

EFSH

FCEL

HTOO

HUHU

MVST

PMEC

SPPL

UAVS

XPON

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) shares rose 55.8% to $3.85 during Friday's pre-market session. The market value of their outstanding shares is at $42.9 million. </li>
<li>Greenidge Generation Holdings Inc. - 8.50% Senior Notes due 2026 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREEL#NASDAQ">GREEL</a>) stock increased by 15.78% to $11.0. </li>
<li>Red Cat Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares moved upwards by 15.42% to $4.64. The market value of their outstanding shares is at $349.8 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares moved upwards by 15.08% to $0.83. The company's market cap stands at $31.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) shares increased by 14.85% to $19.95. The company's market cap stands at $4.7 billion. The company's, Q3 earnings came out 4 days ago. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares moved upwards by 12.76% to $0.6. The market value of their outstanding shares is at $21.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) shares declined by 33.4% to $2.93 during Friday's pre-market session. The market value of their outstanding shares is at $290.3 million. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) shares fell 13.97% to $3.57. The market value of their outstanding shares is at $75.9 million. </li>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) stock decreased by 12.99% to $0.58. The company's market cap stands at $7.9 million. </li>
<li>Mercurity Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) shares decreased by 10.09% to $3.21. The company's market cap stands at $195.2 million. </li>
<li>Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) stock fell 9.5% to $168.34. The market value of their outstanding shares is at $139.3 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares fell 8.1% to $4.2. The company's market cap stands at $41.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

AMAT

BNAI

FOXO

GREE

Greenidge Generation Holdings Inc. - 8.50% Senior Notes due 2026

GREEL

QUBT

RCAT

ZETA

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Offerings

BTCT

BTC Digital Issued 727,425 Shares Via Cashless Exercises In Response To Notices On November 13; Announced An Additional 120,372 Shares Issued On November 15 After Further Exercise Notices

Ratings for Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) were provided by 30 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">14</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">11</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $178.53, with a high estimate of $205.00 and a low estimate of $140.00. Witnessing a positive shift, the current average has risen by 10.03% from the previous average price target of $162.25.
<img src="https://www.benzinga.com/files/images/story/2024/1731704548_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Oracle among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Alex Zukin</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$205.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mark Moerdler</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$202.00</td>
<td>$201.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$157.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$173.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$155.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Jason Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$145.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Oracle. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Oracle compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Oracle's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Oracle's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ORCL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Oracle analyst ratings.</a>
<h2>Delving into Oracle's Background</h2>
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
<h3>Oracle's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Oracle's remarkable performance in 3 months is evident. As of 31 August, 2024, the company achieved an impressive revenue growth rate of 6.86%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Oracle's net margin excels beyond industry benchmarks, reaching 22.01%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Oracle's ROE excels beyond industry benchmarks, reaching 30.01%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Oracle's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.05%, the company showcases efficient use of assets and strong financial health.
Debt Management: Oracle's debt-to-equity ratio is notably higher than the industry average. With a ratio of 7.81, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORCL

Expert Outlook: Oracle Through The Eyes Of 30 Analysts

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OS Therapies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ostx-stock-quote/">OSTX</a>) just reported results for the second quarter of 2024.<ul><li>OS Therapies reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/ostx-stock-earnings-os-therapies-for-q2-of-2024/">OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024

Catalyst Watch: Eyes on tech with Apple, Amazon, Alphabet, and Meta reporting

Meeting to be held with President & CEO Romness and CBO Commissiong on November 6 hosted by Maxim. Published first on TheFly – the ultimate source ...

OS Therapies management to meet with Maxim

This prospectus relates to the resale from time to time by Square Gate Capital Master Fund of OS Therapies (OSTX)' shares of common stock, in an of...

OS Therapies files to sell $15M in common stock for holders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
OS Therapies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ostx-stock-quote/">OSTX</a>) just reported results for the second quarter of 2024.<ul><li>OS Therapies reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/ostx-stock-earnings-os-therapies-for-q2-of-2024/">OSTX Stock Earnings: OS Therapies Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BMEA

CHTR

FFIV

FVRR

GOOG

HSBC

IDCC

INUV

LFVN

LMND

MGPI

MRNS

MSFT

PAPL

PHUN

PTON

QRVO

RDDT

RKLB

RMLFF

SABR

SAVE

SBUX

SVCO

TLTFF

UBER

WHLR

XPEV

Press Releases

OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector

OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

OS Therapies to Present at the LD Micro Main Event XVII

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30

Comments

OS Therapies

OS Therapies (OSTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga